Sufferers of acromegaly, a rare condition often linked with gigantism, may soon have a new option for treatment as Novartis announced positive results of the final-phase trial of its Signifor LAR therapy.
Sufferers of acromegaly, a rare condition often linked with gigantism, may soon have a new option for treatment as Novartis announced positive results of the final-phase trial of its Signifor LAR therapy.